KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Common Equity (2016 - 2025)

Amgen (AMGN) has 17 years of Common Equity data on record, last reported at $8.7 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 47.32% year-over-year to $8.7 billion; the TTM value through Dec 2025 reached $8.7 billion, up 47.32%, while the annual FY2025 figure was $8.7 billion, 47.32% up from the prior year.
  • Common Equity reached $8.7 billion in Q4 2025 per AMGN's latest filing, down from $9.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $9.6 billion in Q3 2025 and bottomed at $916.0 million in Q1 2022.
  • Average Common Equity over 5 years is $6.3 billion, with a median of $6.5 billion recorded in 2021.
  • Peak YoY movement for Common Equity: crashed 90.19% in 2022, then soared 483.84% in 2023.
  • A 5-year view of Common Equity shows it stood at $6.7 billion in 2021, then tumbled by 45.36% to $3.7 billion in 2022, then soared by 70.23% to $6.2 billion in 2023, then decreased by 5.7% to $5.9 billion in 2024, then soared by 47.32% to $8.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $8.7 billion in Q4 2025, $9.6 billion in Q3 2025, and $7.4 billion in Q2 2025.